Delivering complete aseptic vial handling solutions
Bringing freeze drying and vial washing/sterilizing technologies together with advanced and comprehensive vial and syringe filling capabilities.
SP Scientific has signed a new partnership agreement with Lab-i-DOSiTECNO Pharma Technologies enabling both companies to offer complete aseptic vial and syringe fill-finish lines lines for injectable, ophthalmic and oral products in liquid and powder form.
This new global partnership brings together best-in-class freeze drying and vial washing/sterilizing technologies from SP Scientific with the advanced and comprehensive vial and syringe filling capabilities of Lab-i-DOSiTECNO.
Oriol Casòliva, CEO of Lab-i-DOSiTECNO commented: “The geographic synergies of SP Scientific and Lab-iDosiTECNO working together will enable us to provide outstanding local support throughout North America and Europe, significantly broadening the reach of both partners.”
Brian Larkin, CEO of SP Scientific added: “In addition, for those who prefer to work with a single supplier for full lines, this new partnership enables us to provide and support these customers with top quality, highly productive aseptic fill-finish line solutions."
Biopharmaceutical products are often frozen and then thawed, freeze-dried to be rehydrated when needed, or encapsulated in liquid form without being touched by the atmosphere. The container that holds the medicine during transportation through a variety of global climates, and how it is filled, is therefore critical to product integrity. SP Scientific, in partnership with Lab-i-DOSiTECNO, now leads the way in the development and manufacture of complete aseptic vial fill-finish lines offering the broadest lyophilization range available today covering cycle development, stability, pilot and clinical batch production, through to full aseptic manufacturing and commercial production batches.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.